About
About Viva Biotech Holdings
Viva Biotech Holdings, an investment holding company, engages in the provision of structure-based drug discovery services to biotechnology and pharmaceutical customers worldwide. The company provides discovery biology services, including protein expression, structural biology, hit discovery, bioassay, biomolecular interaction, and pharmacology and DMPK; chemistry services, such as medicinal and synthetic chemistry, purification preparation, and computer-aided drug design services, as well as offers chemical technology platforms; and antibody/biologics research and development services comprising recombinant protein expression platform, antibody discovery and affinity maturation, assay platform, antibody production and identification platform, and antigen-antibody structural resolution platform solutions. It also offers PROTAC/molecular glue services, including protein preparation and complex structure determination, ADME & PK/PD studies of PROTAC molecules, and XDC platforms, such as XDC conjugation and quality study, and XDC chemistry research and development. In addition, the company offers contract development and manufacturing services comprising integrated services for small molecule active pharmaceutical ingredients, formulation development and production services, and pharmaceutical analysis services, as well as CMC filing, global filing registration support, and other services. Further, it provides research services. The company was incorporated in 2008 and is headquartered in Shanghai, China.
Research context
Viva Biotech Holdings appears in PyInvesting’s Hong Kong Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- HKD
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Visit company website
5 years, 7 months ago
Viva Biotech Holdings is currently in a long term uptrend where the price is trading 20.8% above its 200 day moving average.
From a valuation standpoint, the stock is 79.1% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 23.5.
Viva Biotech Holdings's total revenue rose by 9.3% to $198M since the same quarter in the previous year.
Its net income has dropped by 341.7% to $-530M since the same quarter in the previous year.
Finally, its free cash flow grew by 126.5% to $10M since the same quarter in the previous year.
Based on the above factors, Viva Biotech Holdings gets an overall score of 4/5.